CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 22 enrolled
Drug / intervention
Terbinafine HCl 250mg tablets +1 moredrug
Likely dose
Terbinafine HCl 250mg tabletsfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00833664
NCT00833664Phase 1Completed
CompareCT.gov

The Relative Bioavailability of Two Terbinafine HCl 250 mg Tablet Formulations Under Non-Fasting Conditions

Teva Pharmaceuticals USA·interventional·Posted Feb 2, 2009·Updated May 30, 2023

In Brief

A Phase 1 clinical trial evaluating Terbinafine HCl 250mg tablets and Lamisil® 250 mg Tablets for Healthy. Completed, enrolled 22 participants across 1 site.

Detailed Summary

The Purpose of this study os to evaluate the relative bioavailability of the test formulation of terbinafine tablets with an already marketed reference formulation Lamisil® (Novartis Pharmaceuticals), under post-prandial conditions in healthy, non-tobacco using male and female adult subjects.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy
CountriesUnited States
Collaborators--

Timeline

Phase 1CompletedFinished
20022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedFeb 2, 2009
Enrollment StartJan 1, 2002
Primary CompletionJan 1, 2002
TodayJul 2, 2026
Enrollment to primary: 0 daysPosted 17.4 years ago

Interventions

Terbinafine HCl 250mg tabletsdrug

1 x 250 mg

Lamisil® 250 mg Tabletsdrug

1 x 250 mg